Retina UK publishes unique insight into the experiences of people with inherited retinal conditions

Retina UK logo

13 September 2019
Source: Retina UK

Evidence of the real-life experiences, challenges and expectations of almost 1,000 people affected by inherited sight loss conditions have been published by national sight loss charity Retina UK. The charity presented some of the key findings from its 2019 Sight Loss Survey when it was invited to represent its community during the recent NICE consultation for the gene therapy Voretigene

Read more Retina UK publishes unique insight into the experiences of people with inherited retinal conditions

BBC News: Gene therapy for rare eye disease set to be offered on NHS

4 September 2019
Source: BBC News

Patients with a rare inherited eye disorder are set to be able to access a new gene therapy on the NHS which slows down sight loss. Draft NICE guidance recommends the therapy (Luxturna) to treat inherited retinal dystrophies. The National Institute for Health and Care Excellence estimates just under 90 people in England will be eligible for the treatment. Drug

Read more BBC News: Gene therapy for rare eye disease set to be offered on NHS

FDA approves Luxturna to treat patients with inherited retinal disease

21 December 2017
Source: FIght for Sight

The US Food and Drug Administration (FDA) has this week approved the first ever gene therapy treatment, Luxturna (Voretigene Neparvovec), for inherited retinal diseases (IRD).The gene therapy drug will be used as a treatment for patients with vision loss caused by RPE65 gene mutations. Mutations in the RPE65 gene are associated with two main types of IRDs – retinitis pigmentosa

Read more FDA approves Luxturna to treat patients with inherited retinal disease